Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim
- 1 May 1997
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 37 (5) , 507-512
- https://doi.org/10.1046/j.1537-2995.1997.37597293882.x
Abstract
BACKGROUND: Multiple days of apheresis are required for some normal peripheral blood progenitor cell (PBPC) donors, to ensure a sufficient collection of CD34+ cells for allografting. It would be of practical value to be able to identify the patients with poor mobilization on the basis of simple pretreatment clinical or hematologic variables.STUDY DESIGN AND METHODS: Clinical characteristics and laboratory data for 119 normal PBPC donors who underwent apheresis on Days 4 to 6 of treatment with granulocyte‐colony‐stimulating factor (filgrastim) were analyzed for correlations with CD34+ cell yield from the first day of apheresis.RESULTS: The CD34+ cell yield was significantly lower in donors who were more than 55 years of age, who underwent apheresis on Day 4 of filgrastim therapy, or who were not obese. There were weak direct correlations between CD34+ cell yield and the baseline white cell count, preapheresis white cell count, and preapheresis mononuclear cell count, and there was a weak inverse correlation with age. Twenty‐ one donors (18%) were considered to have poor mobilization (< 20 × 106 CD34+ cells/L blood processed). In the multivariate analysis, the only significant factor was age greater than 55 years, which conferred a 3.8 times greater risk (95% CI, 1.1–13.7) of poor mobilization (p = 0.04). However, poor mobilization occurred in all age groups, so the predictive value of the model was low.CONCLUSION: Donor variables correlated with CD34+ cell yield only weakly, so no particular clinical characteristic can be used to exclude an individual as a PBPC donor if he or she is otherwise suitable for the apheresis procedure.Keywords
This publication has 24 references indexed in Scilit:
- Clinical toxicity and laboratory effects of granulocyte‐colony‐ stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the proceduresTransfusion, 1996
- Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantationBritish Journal of Haematology, 1996
- Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer.Journal of Clinical Oncology, 1996
- Characterization of peripheral blood progenitor cells (PBPC) mobilized by filgrastim (rHuG‐CSF) in normal volunteers: dose–effect relationship for filgrastim with the character of mobilized PBPCBritish Journal of Haematology, 1996
- G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graftBritish Journal of Haematology, 1994
- Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin.Proceedings of the National Academy of Sciences, 1993
- Hematopoietic Progenitors and Aging: Alterations in Granulocytic Precursors and Responsiveness to Recombinant Human G-CSF, GM-CSF, and IL-3Journal of Gerontology, 1993
- Prednisolone‐Induced GranulocytosisBritish Journal of Haematology, 1968
- Normal Variations with Aging of the Amount of Hematopoietic Tissue in Bone Marrow from the Anterior Iliac Crest: A Study Made from 177 Cases of Sudden Death Examined by NecropsyAmerican Journal of Clinical Pathology, 1965
- A Comparative Study of Bone Marrow Function in Young and Old IndividualsGerontologia Clinica, 1962